The KEYCHAIN trial is the first study to compare radiation therapy with concurrent pembrolizumab, a PD-1 inhibitor, against standard chemoradiotherapy for intermediate risk P16-positive head and neck cancer. We established the safety and preliminary efficacy of this approach in a Phase I lead-in trial, presented this month at the 61st annual ASTRO meeting in Chicago, IL. The randomized trial is being conducted in collaboration with Washington University, Yale University, Moffitt Cancer Center, University of Arizona, and University of Cincinnati.
Sacco AG, Sharabi AN, Jing Z, Pittman E, Gold KA, Sumner W, Califano JA, Brumund KT, Orosco R, Rash D, Coffey CS, Cohen EEW, Mell LK. Radiotherapy with concurrent and adjuvant pembrolizumab in patients with P16-Positive locoregionally advanced head and neck cancer: KEYCHAIN trial lead-in results (abstr.) Int J Radiat Oncol Biol Phys 2019; 105(1):E363-4.